Multimodal Diagnostic Algorithm for CBS and PSP

Multimodal Diagnostic Algorithm for CBS and PSP

Overview

This page describes an integrated diagnostic approach combining multiple biomarker modalities to improve accuracy in differentiating corticobasal syndrome (CBS) from progressive supranuclear palsy (PSP) and other mimics like Parkinson's disease (PD) and Alzheimer's disease (AD)[@multimodal2024].

Diagnostic Modalities

Imaging Biomarkers

| Modality | CBS Findings | PSP Findings | Accessibility |
|----------|--------------|---------------|---------------|
| Tau PET (Flortaucipir) | Asymmetric cortical uptake | Midbrain, globus pallidus uptake | Moderate (specialized centers) |
| Structural MRI | Asymmetric cortical atrophy | Midbrain atrophy, Hummingbird sign | High |
| DTI | Asymmetric frontoparietal WM loss | Superior cerebellar peduncle atrophy | Moderate |
| DaT-SPECT | Asymmetric putaminal deficit | Symmetric caudate/putaminal deficit | High |

Fluid Biomarkers

| Biomarker | CBS Pattern | PSP Pattern | Utility |
|-----------|--------------|--------------|---------|
| CSF NfL | Elevated | Elevated | Disease progression |
| p-tau181/tau217 | Variable | Elevated | Differentiate from AD |
| p-tau231 | May be elevated | Elevated | PSP specificity |
| α-synuclein RT-QuIC | Usually negative | Usually negative | Exclude PD |
| Tau seeding (skin biopsy) | Positive in some | Positive | Emerging |

Clinical Scales

Multimodal Diagnostic Algorithm for CBS and PSP

Overview

This page describes an integrated diagnostic approach combining multiple biomarker modalities to improve accuracy in differentiating corticobasal syndrome (CBS) from progressive supranuclear palsy (PSP) and other mimics like Parkinson's disease (PD) and Alzheimer's disease (AD)[@multimodal2024].

Diagnostic Modalities

Imaging Biomarkers

| Modality | CBS Findings | PSP Findings | Accessibility |
|----------|--------------|---------------|---------------|
| Tau PET (Flortaucipir) | Asymmetric cortical uptake | Midbrain, globus pallidus uptake | Moderate (specialized centers) |
| Structural MRI | Asymmetric cortical atrophy | Midbrain atrophy, Hummingbird sign | High |
| DTI | Asymmetric frontoparietal WM loss | Superior cerebellar peduncle atrophy | Moderate |
| DaT-SPECT | Asymmetric putaminal deficit | Symmetric caudate/putaminal deficit | High |

Fluid Biomarkers

| Biomarker | CBS Pattern | PSP Pattern | Utility |
|-----------|--------------|--------------|---------|
| CSF NfL | Elevated | Elevated | Disease progression |
| p-tau181/tau217 | Variable | Elevated | Differentiate from AD |
| p-tau231 | May be elevated | Elevated | PSP specificity |
| α-synuclein RT-QuIC | Usually negative | Usually negative | Exclude PD |
| Tau seeding (skin biopsy) | Positive in some | Positive | Emerging |

Clinical Scales

| Scale | Domain | CBS Sensitivity | PSP Sensitivity |
|-------|--------|-----------------|-----------------|
| CBD-FRS | Functional rating | High | Moderate |
| PSPRS | PSP rating | Low | High |
| MDS-UPDRS | Motor examination | Variable | Moderate |

Genetic Testing

| Gene | CBS Association | PSP Association |
|------|-----------------|-----------------|
| MAPT | Rare | Common (H1 haplotype) |
| GRN | Associated | Rare |
| C9orf72 | Rare | Rare |
| GBA | Associated | Associated |

Diagnostic Decision Framework

Step 1: Clinical Presentation

Step 2: Imaging Integration

Step 3: Fluid Biomarker Confirmation

Differentiation Algorithms

CBS vs PSP Differentiation

| Feature | Weight | CBS | PSP |
|---------|--------|-----|-----|
| Asymmetry | +2 | +2 | 0 |
| Cortical signs | +2 | +2 | 0 |
| Vertical gaze palsy | +2 | 0 | +2 |
| Early falls | +2 | 0 | +2 |
| Midbrain atrophy | +1 | 0 | +1 |
| PSP-RS criteria | +1 | 0 | +1 |

Score >3: CBS likely Score >5: PSP likely

CBS vs AD Differentiation

| Feature | Weight | CBS | AD |
|---------|--------|-----|-----|
| Parkinsonism | +2 | +2 | 0 |
| Asymmetry | +2 | +2 | 0 |
| Cortical signs | +2 | +2 | 0 |
| Memory prominent | +2 | 0 | +2 |
| Tau PET cortical | +1 | +1 | +2 |
| Hippocampal atrophy | +1 | 0 | +2 |

Score >3: CBS likely Score >3: AD likely

Clinical Utility

Diagnostic Accuracy

| Modality Combination | CBS vs PSP | CBS vs PD | CBS vs AD |
|---------------------|------------|-----------|-----------|
| Clinical only | 65% | 75% | 70% |
| + MRI | 75% | 80% | 78% |
| + Tau PET | 85% | 85% | 82% |
| + CSF biomarkers | 90% | 88% | 88% |
| All combined | 93% | 92% | 90% |

Accessibility Considerations

| Modality | Cost | Availability | Recommendation |
|----------|------|--------------|----------------|
| Clinical exam | $ | High | First-line |
| MRI | $$ | High | Essential |
| Tau PET | $$$ | Moderate | If available |
| CSF analysis | $$ | Moderate | If ambiguous |
| Genetic testing | $$ | Moderate | If young onset |

Implementation

Recommended Workup

Decision Point Summary

Priority-Ranked Diagnostic Tests for CBS/PSP Differentiation

This section ranks all diagnostic tests by priority (1-10) for differentiating corticobasal syndrome (CBS) from progressive supranuclear palsy (PSP), including cost estimates, availability, and turnaround times.

Priority Test Rankings

| Priority | Test | CBS Utility | PSP Utility | Cost (USD) | Turnaround | Key Centers |
|----------|------|-------------|-------------|------------|------------|-------------|
| 10 | Structural MRI (3T) | Asymmetric frontoparietal atrophy | Midbrain atrophy (hummingbird sign) | $500–1,500 | 1–3 days | All major medical centers |
| 9 | Tau PET (Flortaucipir/PI-2620) | Cortical uptake pattern | Midbrain + globus pallidus uptake | $5,000–12,000 | 3–7 days | UCSF, Mayo, Cleveland Clinic, Banner, UCLA |
| 8 | CSF Biomarker Panel (p-tau181, p-tau217, NfL, GFAP) | Elevated NfL, variable p-tau | Elevated p-tau231, p-tau217 | $800–2,000 | 5–14 days | Major academic centers, reference labs |
| 8 | Plasma p-tau217/NfL | Moderate elevation | Elevated NfL | $150–500 | 3–7 days | Quest, LabCorp, Mayo Labs, Fujirebio certified labs |
| 7 | FDG-PET | Asymmetric parietal/frontal hypometabolism | Midbrain, frontal hypometabolism | $2,500–5,000 | 3–7 days | UCSF, Mayo, MD Anderson, Mass General |
| 7 | DaT-SPECT (Ioflupane) | Asymmetric putaminal deficit | Symmetric caudate/putaminal deficit | $1,500–3,000 | 3–5 days | Most nuclear medicine centers |
| 6 | Blood Biomarker Panel (NfL, GFAP, p-tau181) | Elevated NfL | Elevated GFAP, NfL | $100–350 | 3–7 days | Quest, LabCorp, Neurodegenerative Research Labs |
| 5 | Genetic Testing (MAPT, GRN, GBA, C9orf72) | GRN, GBA associated | MAPT H1 haplotype | $500–3,000 | 4–8 weeks | Invitae, GeneDx, Mayo Genetic Testing |
| 5 | Skin Biopsy (Tau Seeding Assay) | Positive in ~50% CBS | Positive in ~40% PSP | $1,500–3,000 | 2–4 weeks | Cleveland Clinic, UCSF, specialized reference labs |
| 4 | MRI Volumetry (automated) | Quantifies cortical atrophy | Quantifies midbrain atrophy | $800–1,500 | 3–5 days | VUAI, NeuroQuant certified centers |
| 4 | Saccade Testing (EOG/Video-oculography) | Variable, hypometria | Vertical supranuclear gaze palsy | $200–500 | Same day | Movement disorder centers |
| 4 | Cardiac MIBG Scintigraphy | Usually normal | Reduced uptake (sympathetic denervation) | $1,000–2,000 | 3–5 days | Specialized nuclear cardiology centers |
| 3 | Amyloid PET (Florbetapir/Flutemetamol) | Rule out AD comorbidity | Rule out AD comorbidity | $3,000–8,000 | 3–7 days | UCSF, Banner, Mayo, Avid Radiopharmaceuticals |
| 3 | DTI/Advanced Diffusion MRI | Asymmetric frontoparietal WM loss | Superior cerebellar peduncle atrophy | $1,000–2,000 | 3–7 days | Academic centers with research protocols |
| 2 | Transcranial Sonography | Not standard | Not standard | $200–400 | Same day | Limited availability |
| 1 | Neuropsychological Testing | Cortical deficits prominent | Subcortical deficits prominent | $1,500–4,000 | 2–4 weeks | Neuropsychology practices |

Detailed Test Descriptions

Tier 1: Essential Tests (Priority 8–10)

1. Structural MRI (Priority 10)

• Cost: $500–1,500 (insurance typically covers)
• Turnaround: 1–3 days
• Availability: Virtually all hospitals and imaging centers
• CBS findings: Asymmetric frontoparietal cortical atrophy, putaminal atrophy
• PSP findings: Midbrain atrophy, "hummingbird sign," superior frontal atrophy
• Recommendation: First-line, essential for all cases

• Cost: $5,000–12,000 (often requires prior authorization)
• Turnaround: 3–7 days for scheduling + 1–2 days for results
• Availability: Major academic centers with PET scanners
• Key Centers:
• UCSF Memory and Aging Center: (415) 353-2063
• Mayo Clinic Rochester: (507) 284-2511
• Cleveland Clinic: (216) 444-2030
• Banner Alzheimer's Institute: (602) 839-6900
• UCLA Neuroscience Center: (310) 794-6311
• Tracers: Flortaucipir (FDA-approved), PI-2620, MK-6240
• CBS pattern: Asymmetric cortical uptake
• PSP pattern: Midbrain and globus pallidus uptake
• Recommendation: Strongly recommended when available to confirm tauopathy

• Cost: $800–2,000
• Turnaround: 5–14 days
• Availability: Major academic centers, reference laboratories
• Panel includes:
• Total tau (t-tau): Elevated in both CBS/PSP
• Phosphorylated tau (p-tau181, p-tau217): Variable, higher in PSP
• p-tau231: Higher in PSP, more specific
• Neurofilament light (NfL): Markedly elevated in atypical parkinsonism
• GFAP: Elevated in PSP vs. PD
• Recommendation: Recommended for ambiguous cases

• Cost: $150–500 (significantly cheaper than CSF)
• Turnaround: 3–7 days
• Availability: Widely available through major labs
• Key labs:
• Quest Diagnostics: p-tau181, NfL
• LabCorp: NfL, GFAP
• Mayo Medical Laboratories: p-tau217 (research use)
• Fujirebio (Lumipulse G): p-tau217/Aβ42 ratio (FDA-approved for AD)
• Recommendation: First-line screening test, more accessible than CSF

Tier 2: Recommended Tests (Priority 5–7)

5. FDG-PET (Priority 7)

• Cost: $2,500–5,000
• Turnaround: 3–7 days
• Key Centers: UCSF, Mayo Clinic, MD Anderson, Massachusetts General Hospital
• CBS pattern: Asymmetric parietal/frontal hypometabolism
• PSP pattern: Midbrain, superior frontal, caudate hypometabolism

• Cost: $1,500–3,000
• Turnaround: 3–5 days
• Availability: Most nuclear medicine departments
• Utility: Differentiates dopaminergic degeneration from non-degenerative causes

• Cost: $500–3,000 depending on panel scope
• Turnaround: 4–8 weeks
• Testing options:
• MAPT gene: PSP association (H1 haplotype)
• GRN gene: CBS association
• GBA gene: Both CBS and PSP association
• C9orf72: Rare in both
• Providers: Invitae, GeneDx, Athena Diagnostics, Mayo Genetic Testing

• Cost: $1,500–3,000
• Turnaround: 2–4 weeks
• Key Centers:
• Cleveland Clinic: (216) 444-2030
• UCSF: (415) 353-2063
• Translational Genomics Research Institute (TGen)
• Utility: Detects tau protein seeding activity in skin fibroblasts

Tier 3: Specialized Tests (Priority 1–4)

9. MRI Volumetry (Priority 4)

• Services: NeuroQuant, VUAI (Volumetric USI)
• Cost: $800–1,500 (often included in MRI cost)
• Turnaround: 3–5 days

• Cost: $200–500
• Availability: Movement disorder specialists, research centers
• Method: Video-oculography (VOG) or electro-oculography (EOG)

• Cost: $1,000–2,000
• Turnaround: 3–5 days
• Utility: Differentiates from Lewy body disease (reduced uptake in LBD, normal in CBS/PSP)

• Tracers: Florbetapir (Amyvid), Flutemetamol (Vizamyl), Florbetaben (Neuraceq)
• Cost: $3,000–8,000
• Utility: Rule out AD comorbidity (positive in CBS+AD or PSP+AD)

Cost-Effective Diagnostic Algorithm

Budget-Conscious Approach:

Geographic Availability by Region

United States — Major Centers:

| Region | Center | Tests Available |
|--------|--------|-----------------|
| West Coast | UCSF Memory Center | MRI, Tau PET, FDG-PET, CSF, Genetic |
| West Coast | UCLA Brain Institute | MRI, Tau PET, FDG-PET |
| Midwest | Mayo Clinic Rochester | All modalities |
| Midwest | Cleveland Clinic | MRI, Tau PET, Skin biopsy, CSF |
| Northeast | Mass General Hospital | MRI, Tau PET, FDG-PET |
| Southwest | Banner Alzheimer's Institute | MRI, Tau PET, Amyloid PET |
| Texas | MD Anderson | MRI, FDG-PET, CSF |

United Kingdom:

• UCL Queen Square: All advanced imaging
• Cambridge Memory Clinic
• Oxford Neurology

• German Center for Neurodegenerative Diseases (DZNE)
• Paris Brain Institute (ICM)

Insurance Coverage Notes

• Medicare: Covers MRI, CT, basic PET with clinical indication
• Private Insurance: Prior authorization often required for Tau PET, advanced PET
• Self-Pay: Most centers offer discounted rates (30–50% reduction)
• Clinical Trials: Often provide free advanced diagnostics

Emerging Tools

• Automated MRI analysis: Machine learning for atrophy patterns
• Digital biomarkers: Speech, gait analysis apps
• Blood biomarkers: Plasma p-tau, NfL becoming available
• Olfactory testing: May help differentiate

See Also

• [Corticobasal Syndrome](/diseases/corticobasal-degeneration)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [CBD-FRS Scale](/diagnostics/cbdf-scale)
• [Tau PET Imaging](/diagnostics/tau-pet-imaging)
• [CSF Biomarkers](/diagnostics/csf-biomarkers)